AAR Chairman, President and CEO John McClain Holmes III Reports Sale of $3.41 Million in Common Shares
Bitget2026/10/28 15:18- AAR Chairman, President and CEO John McClain Holmes III sold 35,000 shares of common stock on Oct. 26, 2026.
- The reported sale price was $97.4051 per share. His direct holdings totaled 406,362 shares following the transaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation

Forge Nano completes acquisition of HzO